Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia

Australian and New Zealand Journal of Public Health

Volumn 29, Issue 6, 2005, Pages 544-551

  Gidding, Heather F ^a,b   Brisson, Marc ^c   Macintyre, C Raina ^a   Burgess, Margaret A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CHICKENPOX; CHILD; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INCIDENCE; INFANT; INFECTION CONTROL; INFECTION RISK; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MORBIDITY; POPULATION DISTRIBUTION; SEROPREVALENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VARICELLA ZOSTER VIRUS;

EID: 28944434192     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2005.tb00248.x     Document Type: Article

References (30)

1. McIntyre P, Gidding H, Gilmour R, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell. 2001;Suppl:i-xi.
2. Australian Institute of Health and Welfare. National Hospital Mortality database, 1998-99 & 1999-00. Canberra: Australian Institute of Health and Welfare; 2005 June 30. Available from: http://www.aihw.gov.au/hospitals/daracubes/datacube_pdx.cfm [cited 2005 November 3].
3. Takahashi M. Development and characteristics of Oka strain of live varicella vaccine. Acta Paediatr Jpn. 1988;30:185-93.
4. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr. 1995;127:518-25.
5. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. J Am Med Assoc. 2002;287:606-11.
6. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Eng J Med. 2005;352:450-8.
7. Schuette MC, Hethcote HW. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol/1999;61:1031-64.
8. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunisation on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125:651-69.
9. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl 1):31-7.
10. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-12.
11. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20:2500-7.
12. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case control study. Lancet. 2002;360:678-82.
13. Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect. 2003;131:1085-9.
14. Farrington CP. Modelling forces of infection for measles, mumps and rubella. Stat Med. 1990;9:953-67.
15. Anderson RM, May RM. Infectious Diseases of Humans. Oxford (UK): Oxford University Press; 1999.
16. Australian Institute of Health and Welfare. Australian Hospital Statistics 2001-02. Canberra (AUST): AIHW; 2003. Health Services Series No.: 20.
17. Communicable diseases surveillance, additional reports: childhood immunisation coverage. Commun Dis Intell. 2003;27:569-70.
18. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
19. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305-14.
20. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis. 1983;148:200-5.
21. Solomon BA, Kaporis AG, Glass AT, Simon SI, Baldwin HE. Lasting immunity to varicella in doctors study (L.I.V.I.D. study). Am Acad Dermatol. 1998;38:763-5.
22. Terada K, Hiraga Y, Kawano S, Kataoka N. Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster. Kansenshogaku Zasshi. 1995;69:908-12.
23. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20:1113-25.
24. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003;88:862-9.
25. Goldman GS. Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage. Vaccine. 2003;4243-9.
26. Seward JF, Jumaan AO, Galil K, Wharton M. Varicella vaccine and shingles [letter]. J Am Med Assoc. 2002;287:2211-12.
27. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:2002-7.
28. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909-15.
29. Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 2003;21:13-38.
30. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. J Am Med Assoc. 2004;291:851-5.